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tin (rhEPO) has been therapeutically 
used for correction of anaemia. How-
ever, due to the increase in circulating 
red blood cells (RBCs) it promotes, 
thus increasing oxygen delivery to 
muscles and improving performance 
in sport, it has been also illegally used 
as sports doping. Besides the well 
known increase of hematocrit and 
blood viscosity, which might cause 
serious complications for the athletes, 
other disturbances could occur, whose 
mechanisms remain to be fully eluci-
dated. This study aimed to evaluate 
the hemorheological and cardiovas-
cular effects of administration of 
rhEPO to rats under chronic aerobic 
exercise. A ten week-protocol was 
performed in four male Wistar rat 
groups: control – sedentary; rhEPO 
– 50 IU/kg, 3 times/wk; exercised 
(EX) – swimming for 1hr, 3 times/
wk; EX+rhEPO. rhEPO in trained 
rats promoted erythrocyte count in-
crease, hypertension, heart hypertro-
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phy, sympathetic and serotonergic 
overactivation, as well as a trend to 
increased oxidative stress. In conclu-
sion, rhEPO doping in rats under 
chronic exercise promotes not only 
the expected increased hematocrit, 
but also other serious deleterious car-
diovascular and thromboembolic 
modifications, including live risk, 
which might be known and assumed 
by all sports authorities, including 
athletes and their physicians.
(Key-words: rhEPO, doping, 
chronic aerobic exercise, hemorheo-
logical and cardiovascular effects).
INTRODUCTION
Recombinant human erythropoi-
etin (rhEPO) doping remains a huge 
concern, not only because of distor-
tion of sport truth, but particularly 
because of the risks for athletes under 
doping administration. Besides the 
well known increase of hematocrit 
and blood viscosity, other hemorheo-
logical and cardiovascular distur-
bances could occur, but the mecha-
nisms underlying remain to be 
elucidated.
Erythropoietin (EPO) is a glyco-
protein hormone synthesized pre-
dominantly in the kidneys which 
stimulates proliferation and matura-
tion of erythroid cells in the bone 
marrow1. The production of recom-
binant human erythropoietin (rhEPO), 
which has been widely used for cor-
rection of anaemia, allowed many 
patients for the fi rst time to resume 
their normal daily activities due to 
increased energy2. The increase in 
circulating red blood cells (RBCs) 
may be used to increase oxygen de-
livery to muscles, improving per-
formance in sport3. The availability 
of rhEPO allowed its use in doping. 
As soon as the anti-doping authorities 
were able to distinguish between the 
endogenous and the rhEPO4, the 
scandal of its use in sport was re-
vealed, with particular emphasis to 
cycling and cross-country skiing, be-
tween other sport modalities5-6. Sports 
authorities prohibited the use of 
rhEPO in 1988. The idea was, fi rst, 
to limit the degree of health risk and, 
second, the degree of performance 
enhancement.
Athletes who abuse rhEPO con-
sider only the benefi t to performance 
and usually ignore the potential short 
and long-term liabilities7-8. In the 
early 1990s, there was a considerable 
speculation about the involvement of 
rhEPO doping in the death of profes-
sional cyclists8-9. The artifi cial in-
crease in RBC count and haematocrit, 
further enhanced by dehydratation 
during prolonged exercise, predis-
poses to thromboembolic complica-
tions, which might be connected to 
sudden death in sport practice10. 
However, the cellular/molecular 
mechanisms underlying those sudden 
death episodes are poorly clarifi ed, as 
well as whether rhEPO use was linked 
to this outrageous phenomenon.
The purpose of this study was to 
evaluate the hemorheological and 
cardiovascular effects of rhEPO treat-
ment on rats under chronic aerobic 
exercise.
MATERIAL AND METHODS
Animals and experimental protocol
Male Wistar rats (Charles River 
Laboratories Inc., Barcelona, Spain), 
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weighting 220-250g, were maintained 
in an air conditioned room (22-24ºC) 
with humidity of 60%, subjected to 
12-h dark-light cycles and given stan-
dard rat chow (AO4, Panlab, Letica, 
Barcelona, Spain) and water ad libi-
tum. All experiments with animals 
were performed in accordance with 
the European Convention for the Pro-
tection of Vertebrate Animals used for 
Experimental and other Scientific 
Purposes (Council of Europe n.er 123, 
Strasbourg, 1985), as well as with 
ethical laws of the National Institu-
tions for Science and Technology.
After a period of adaptation of at 
least 2 weeks, four groups (n=8 each) 
were evaluated for 10 weeks-treat-
ment: a) control – sedentary; b) rhEPO 
– 50 IU/Kg/3x/wk of s.c. beta-EPO 
(Recormon®, Roche Pharmaceuti-
cals); c) exercised (EX) – swimming 
training (1 hr, 3x/wk); d) swimming 
exercised + rhEPO (EX+rhEPO). The 
swimming groups were submitted to 
a previous adaptation period of 1 
week in order to minimize the stress 
caused by water. These sessions star-
ted with 15 min in the fi rst day, with 
an increment of 5 min each day until 
achieved a period of continuous 60 
min. After this period, the exercise 
was performed for 1 h, 3x/week, in a 
temperature-controlled bath set at 
35±1ºC, for 10 weeks.
Body weight (BW) was monitored 
during the study, and blood pressure 
(BP) and heart rate (HR) measured 
using a tail-cuff sphygmomanometer 
LE 5001 (Letica, Barcelona, Spain).
Sample collection and preparation
Blood: At the end of treatments the 
rats were subjected to intraperitoneal 
anesthesia with a 2 mg/kg BW of a 2:1 
(v:v) 50 mg/mL ketamine (Ketalar®, 
Parke-Davis, Lab. Pfeizer Lda, Seixal, 
Portugal) solution in 2.5% chlorpro-
mazine (Largactil®, Rhône-Poulenc 
Rorer, Lab. Vitória, Amadora, Portu-
gal) and blood samples were immedia-
tely collected by venipuncture from 
the jugular vein into syringes without 
anticoagulant (for serum samples col-
lection) or with the appropriate anti-
coagulant: EDTA, heparin or a solu-
tion of ACD (acid citrate-dextrose). 
Blood was centrifuged (160 g for 10 
min. at 20ºC) to obtain platelet rich 
plasma (PRP), which was then centri-
fuged (730 g for 10 min. at 20ºC) to 
obtain the platelet pellet and poor 
platelet plasma (PPP).
Tissues: The rats were sacrifi ced by 
cervical dislocation and the heart, the 
adrenals, the kidneys, the liver and the 
gastrocnenius muscle were immedia-
tely removed, placed in ice-cold Krebs’ 
buffer and carefully cleaned of adhe-
rent fat and connective tissue. The BW 
and the weights of heart (HW), left 
ventricle (LVW), adrenals (AW), kid-
ney (KW), liver (LW) and muscle 
(MW) were measured in all the rats 
under study in order to be used as tro-
phy indexes. The following tissues 
were removed from the rat that suf-
fered a sudden death episode during an 
exercise session after 8 weeks of treat-
ment: lungs, kidneys, brain, heart/left 
ventricle and liver. Tissues were ana-
lyzed for histomorphology with hae-
matoxilin-eosin (H&E) staining.
Serum Epo concentration 
and haematological data
Serum erythropoietin was mea-
sured by using an immunoassay kit 
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(R&D Systems, Minneapolis, USA). 
Results were expressed in pg/ml. Red 
blood cell (RBC) count, haematocrit 
(Hct), haemoglobin (Hb) concentra-
tion, haematological indices [mean 
cell Hb (MCH) and mean cell Hb 
concentration (MCHC), mean cell 
volume (MCV) and red cell distribu-
tion width (RDW)], platelet count 
and platelets indices [plaquetocrit 
(PCT), mean platelet volume (MPV) 
and platelet distribution width 
(PDW)] were assessed in an auto-
matic Coulter Counter® (Beckman 
Coulter Inc., USA, CA).
Renal and liver function 
and lipid profi le
Serum creatinine, ureia and uric 
acid concentrations were used as re-
nal function indexes and aspartate 
(AST) and alanine aminotransferase 
(ALT) levels were assessed for liver 
evaluation, through automatic valida-
ted methods and equipments (Hitachi 
717 analyser).
Serum total cholesterol (Total-c) 
and triglycerides (TGs) were analy-
sed on a Hitachi 717 analyser (Roche 




Noradrenaline (NA) and adrena-
line (A) concentrations in plasma, 
platelet, adrenals and brain, as well 
as plasma, platelet and brain 5-hy-
droxy-tryptamine (5-HT) and 5-hy-
droxyindoleacetic acid (5-HIAA) 
contents, were evaluated by high per-
formance liquid chromatography 
with electrochemical detection 
(HPLC-ED), according to previously 
described11, using appropriate stand-
ards (Sigma Chemical Co., St. Louis, 
MO, U.S.A.) and software (Gilson 
710). Concentrations were expressed 
in: ng/ml for plasma and platelets and 
μg/g wet tissue for adrenals and 
brain.
Serum infl ammatory profi le 
and redox status
Inflammatory markers: Serum 
levels of interleukin 2 (IL-2), IL-1β, 
transforming growth factor β1 
(TGF-β1) and tumour necrosis fac-
tor α (TNF-α) were measured by 
ultrasensitive Quantikine® ELISA 
kits (R&D Systems, Minneapolis, 
USA) and C-reactive protein (CRP) 
by using an ELISA kit from Helica 
Biosystems, Inc. (Fullerton, CA, 
USA). All assays were performed in 
duplicate.
Redox status: The thiobarbituric 
acid reactive-species (TBARs) assay 
was used to assess serum and muscle 
products of lipid peroxidation, via 
malondialdehyde (MDA), according 
to previously described12. Samples 
were analysed spectrophotometri-
cally at 532 nm using 1,1,3,3-tetram-
ethoxypropane as external standard. 
The serum concentration of lipid per-
oxides (in MDA) was expressed as 
μmol/l. Serum 3-nitrotyrosine (3-
NT), which is an index of peroxynitrite 
formation, was measured through an 
enzymatic immunoassay (HyCult 
biotechnology b.v., Uden, Nether-
lands). Ferric reducing antioxidant 
potential (FRAP) assay was used to 
estimate serum total antioxidant sta-
tus (TAS)13.
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Data analysis
For statistical analysis, we used 
the Statview 4.53 software from Ab-
acus Concepts Inc. (Berkeley, CA, 
USA). Results are presented as mean 
± standard error of the mean (s.e.m.). 
Comparisons between groups were 
performed using Factorial ANOVA 
and Fisher’s test. Signifi cance was 
accepted at P less than 0.05.
RESULTS
Serum EPO concentration 
and haematological data
Serum EPO concentrations at the 
end of treatments were signifi cantly 
higher (P<0.05) in the rhEPO rats 
when compared with the controls, 
while no signifi cant differences were 
encountered in the EX animals. rhE-
PO treatment in the exercised rats 
(group EX+rhEPO) did not signifi -
cantly modify the serum EPO con-
centrations (Table I).
The rats under rhEPO treatment 
showed an increase in RBC count 
(P<0.05) when compared with the 
control. This was accompanied by 
increased (P<0.05) MCHC and 
MCV, together with a decreased 
MPV (Table I). The exercised rats 
demonstrated no relevant changes 
concerning haematological data, ex-
cepting higher MCHC and lower 
MPV vs the control animals. In the 
exercised rats treated with rhEPO, 
there was a statistically signifi cant 
increment in RBC count, together 
with a trend to increased Hb and Hct 
vs the EX rats without rhEPO thera-
py. Platelet count and PCT also sho-
wed a trend to higher values in this 
group (Table I).
Table I – Serum EPO concentration and hemorheological data
Parameters
Sedentary Swimming
Control (n=7) rhEPO (n=7) EX (n=7) EX+rhEPO (n=7)
Serum [EPO] (pg/ml) 22.25 ± 1.00 35.75 ± 10.1a 27.83 ± 1.50  25.75 ± 2.24
Hemorheological data
RBC count (×1012/L) 7.31 ± 0.16 7.67 ± 0.08a  7.59 ± 0.15  8.23 ± 0.14b
Hb (g/dL) 14.45 ± 0.65 14.11 ± 0.15 14.86 ± 0.25  15.45 ± 0.45
Hct (%) 41.45 ± 1.65 39.59 ± 0.45 41.40 ± 0.82  44.05 ± 1.45
MCH (pg) 19.80 ± 1.30 18.76 ± 0.22 19.60 ± 0.34  18.75 ± 0.25
MCHC (g/dl) 34.80 ± 0.20 35.75 ± 0.18a 35.93 ± 0.21a  35.05 ± 0.05
MCV (fl ) 56.80 ± 3.50 52.48 ± 0.60a 54.61 ± 1.13  53.55 ± 0.85
RDW (%) 15.25 ± 0.65 15.89 ± 0.38 14.84 ± 0.55  14.25 ± 0.15
Platelet count (×109/L) 904.0 ± 9.0 986.3 ± 41.5 1008.4 ± 35.9 1021.0 ± 57.0
PCT (%)  0.55 ± 0.02 0.56 ± 0.02  0.57 ± 0.02  0.60 ± 0.07
MPV (fL)  6.15 ± 0.25 5.69 ± 0.06a  5.63 ± 0.14a  5.85 ± 0.35
PDW (%) 16.85 ± 0.15 16.73 ± 0.18 16.37 ± 0.26  17.00 ± 0.10
Results are means ± s.e.m. of n rats per group. a P<0.05, aa P<0.01 and aaa P<0.001 vs the sedentary group (control); b P<0.05, bb P<0.01 and bbb P<0.001 vs the 
Swimming group without rhEPO (exercise: EX). EPO, erythropoietin; Hb, haemoglobin; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular 
haemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; PCT, plateletocrit; PDW, platelet distribution width; RBC, red blood 
cell; RDW, red deviation weight; rhEPO, recombinant human erythropoietin
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Renal and liver function 
and lipid profi le
Urea content was lower (P<0.05) 
in the rhEPO group vs control, wi-
thout signifi cant changes on creatinine 
and uric acid. Exercised rats also pre-
sented signifi cantly lower values of 
urea (P<0.05) and uric acid (P<0.01). 
This reduction was prevented in the 
rats under exercise and rhEPO treat-
ment (EX+rhEPO) (Table II).
Serum AST was unchanged betwe-
en groups, and ALT was identical for all 
the groups, excepting for a lower value 
in the control animals (Table II).
Concerning the lipid profi le, whi-
le the rhEPO rats presented a trend to 
higher Total-c contents and signifi -
cantly increased TGs levels (P<0.05), 
the EX animals showed the opposite 
profi le. The values encountered for 
the EX+rhEPO rats were similar to 
those of the EX animals (Table II).
Blood pressure and tissue weights
Blood pressure (SBP, DBP and 
MBP) and HR values were higher in 
the rfEPO group when compared 
with control. The same pattern was 
found for EX group. In exercised 
animals, rhEPO treatment further in-
creased blood pressures (P<0.001) 
and HR (P<0.05) (Table III). Body 
weight showed a lower value in EX 
rats vs control, without further chang-
es between groups. HW and HW/BW 
were signifi cantly higher in rhEPO 
group vs control, together with sig-
nifi cant lower LVW and LVW/BW. 
In the rats under exercise practise, 
rhEPO treatment promoted a further 
increment in HW and HW/BW, with 
a trend to increased values of LVW 
and LVH/BW (Table III). Concerning 
the other tissues, in the rhEPO group 
there was a signifi cant reduction of 
(P<0.05) KW/BW, while in the rats 
under exercise there were higher va-
lues of LVW/BW, AW/BW and MW/
BW (Table III).
Table II – Effects of rhEPO on renal function, liver function and lipid profi le
Parameters
Sedentary Swimming
Control (n=7) rhEPO (n=7) EX (n=7) EX+rhEPO (n=7)
Renal Function
Urea (mg/dL) 18.84 ± 0.55 17.37 ± 0.46a 17.35 ± 0.26a 18.60 ± 0.63
Creatinine (mg/dL) 0.57 ± 0.01 0.54 ± 0.02 0.57 ± 0.01 0.56 ± 0.01
Uric acid (mg/dL) 0.68 ± 0.05 0.77 ± 0.05 0.40 ± 0.06aa 0.50 ± 0.03
Liver Function
AST (IU/L) 27.20 ± 0.37 27.50 ± 0.50 30.60 ± 2.84 32.40 ± 2.27
ALT (IU/L) 50.20 ± 0.86 70.00 ± 2.28aaa 65.20 ± 1.59aaa 63.50 ± 2.63
Lipid Profi le
Total-c (mg/dL) 53.17 ± 1.66 55.00 ± 1.94  43.67 ± 1.20aa  38.25 ± 1.18
TGs (mg/dL) 151.80 ± 7.17 185.60 ± 16.21a 131.00 ± 5.58 136.33 ± 8.03
Results are means ± s.e.m. of n rats per group. a P<0.05, aa P<0.01 and aaa P<0.001 vs the sedentary group (control); b P<0.05, bb P<0.01 and bbb P<0.001 vs the 
Swimming group without rhEPO (exercise: EX). ALT, alanine aminotransferase; AST, aspartate aminotransferase; rhEPO, recombinant human erythropoietin; 
TGs, triglycerides; Total-c: total cholesterol
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Sympathetic and serotonergic 
measures
The rhEPO-treated rats presented 
a trend to higher values of plasma NA 
and AD vs control, together with low-
er platelet contents of both catecho-
lamines and of NA in adrenals. Exer-
cised rats also showed a trend to 
higher concentration of plasma NA 
and signifi cantly higher (P<0.001) of 
platelet NA and AD, as well as lower 
content in the adrenals, which was 
statistically significant for AD 
(P<0.05). In the EX+rhEPO rats, 
however, the plasma NA and AD were 
signifi cantly (P<0.05) higher when 
compared with EX group, which was 
accompanied by lower platelet AD 
content and a trend to higher concen-
tration of this amina in adrenals and 
brain (Table IV). Concerning sero-
toninergic measures, while plasma 
5-HT values were lower (P<0.01) in 
rhEPO rats vs control, 5-HIAA levels 
were higher (P<0.01). Similar pattern 
was found for the EX animals 
(P<0.05). The platelet levels showed 
an inverse profi le. In the rats under 
exercise and rhEPO treatment, the 
plasma 5-HT (P>0.001) and 5-HIAA 
(P<0.05) concentrations were sub-
Table III – Effects of rhEPO on BP, HR and tissue trophy indexes in chronic exercise
Parameters
Sedentary Swimming
Control (n=7) rhEPO (n=7) EX (n=7) EX+rhEPO (n=7)
Blood Pressure and HR
SBP (mmHg) 116.60 ± 0.70 120.00 ± 1.53a 123.92 ± 1.38a  136.67 ± 1.08bbb
DBP (mmHg)  94.60 ± 1.00 110.67 ± 0.88aa  108.33 ±1.34aa  123.22 ± 2.04bbb
MBP (mmHg) 100.10 ± 0.70 113.67 ± 0.88a 113.25 ± 0.99a  127.33 ± 1.62bbb
HR (beats/min.) 341.30 ± 3.00 407.33 ± 13.93 394.58 ± 8.66  418.44 ± 6.57b
Body and Tissue Weights
BW (Kg)  0.51 ± 0.01  0.48 ± 0.10  0.46 ± 0.10a  0.46 ± 0.09
HW (g)  1.19 ± 0.03  1.31 ± 0.05a 1.23 ± 0.03  1.40 ± 0.03bb
LVW (g)  0.57 ± 0.02 0.42 ± 0.02aaa 0.58 ± 0.02  0.62 ± 0.02
KW (g)  1.42 ± 0.05 1.24 ± 0.04aa  1.23 ± 0.06aa  1.33 ± 0.04
LW (g) 16.78 ± 0.52 15.27 ± 0.43a  15.62 ± 0.61 15.42 ± 0.38
AW (g) 0.057 ± 0.002 0.054 ± 0.01 0.069 ± 0.009 0.083 ± 0.008
MW(g) 23.57 ± 0.80 20.47 ± 1.1a  22.46 ± 0.47  22.39 ± 0.83
Tissue Trophy Indexes
HW/BW (g/kg)  2.35 ± 0.05  2.72 ± 0.10a  2.65 ± 0.10  3.06 ± 0.16b
LVW/HW (g/kg)  0.48 ± 0.02  0.38 ± 0.02aaa  0.52 ± 0.01  0.45 ± 0.01b
LVW/BW (g/kg)  1.12 ± 0.06  0.89 ± 0.03aa  1.32 ± 0.09a  1.38 ± 0.04
KW/BW (g/kg)  2.86 ± 0.09  2.56 ± 0.05a  2.66 ± 0.13  2.82 ± 0.10
LW/BW (g/kg) 32.92 ± 0.57 31.72 ± 0.59 33.65 ± 1.15 34.34 ± 0.65
AW/BW (g/kg) 0.108 ± 0.01 0.114 ± 0.02 0.148 ± 0.02a 0.175 ± 0.02
MW/BW (g/kg) 44.90 ± 0.91 45.06 ± 0.31 47.75 ± 0.59aa 46.10 ± 0.46
Results are means ± s.e.m. a p< 0.05, aa – p< 0.01 and aaa – p< 0.001 vs the control and b p< 0.05, bb – p< 0.01 and bbb – p< 0.001 vs the EX group without 
rhEPO. AW, adrenals weight; BW: body weight; DBP, diastolic blood pressure; HR, heart rate; HW, heart weight; KW, kidney weight; LVW, left ventricle 
weight; LW, liver weight; MBP, mean blood pressure; MW, muscle weight; SBP, systolic blood pressure
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stantially higher than those observed 
in EX animals and the platelet and 
brain levels were maintained identical 
to those of the EX rats (Table IV).
Serum infl ammatory profi le 
and redox status markers
In the rhEPO rats there was sig-
nifi cantly (P<0.05) higher values of 
TNF-α and TGF-β1 vs control. No 
signifi cant changes were obtained for 
the EX group vs control. In the 
EX+rhEPO group, excepting the high-
er (P<0.05) values of TGF-β1 vs the 
EX group, there was no further diffe-
rences between the groups (Table V).
In the rhEPO-treated rats (rhEPO 
group) there was an antioxidant effect, 
with an increment in TAS (P<0.001) 
and a decrease in 3-NT content 
(P<0.05). Similar pattern was found 
for the EX group vs control, particu-
larly due to a decrease in serum MDA 
(P<0.05). However, in the rats of the 
EX+rhEPO group, the effect was pro-
oxidant, with a trend to lower levels 
of TAS and higher of MDA, MDA/
TAS and 3-NT vs the EX (Table V).
DISCUSSION
The rationale for its use in sport, 
as doping, is, thus, based on the in-
creased oxygen capacity it provides, 
due to augmented erythropoietic 
stimulation3. Since rhEPO became 
available as an erthropoiesis-stimu-
lating drug, its abusing use by ath-
letes of endurance aerobic sports has 
been speculated and studied2,5,6. 
rhEPO doping remains one of the 
Table IV – Effects of rhEPO on peripheral and central catecholamine and serotonin measures
Parameters
Sedentary Swimming
Control (n=7) rhEPO (n=7) EX (n=7) EX+rhEPO (n=7)
Catecholamines Measures
NA – Plasma (ng/ml) 3.71 ± 0.60 4.81 ± 0.37 5.10 ± 0.96 9.32 ± 1.43b
Platelet (ng/ml) 4.54 ± 0.61 0.60 ± 0.08aaa 8.02 ± 0.68 aaa 7.01 ± 0.47
Adrenals (μg/g) 164.1 ± 8.0 130.4± 9.6a 149.8 ± 15.8 133.8 ± 7.9
Brain (ng/g) 0.20 ± 0.004 0.18 ± 0.007 0.21 ± 0.008 0.19 ± 0.008
AD – Plasma (ng/ml) 1.48 ± 0.21 1.52 ± 0.06 1.04 ± 0.09 1.96 ± 0.18b
Platelet (ng/ml) 0.69 ± 0.04 0.36 ± 0.08aa 9.15 ± 2.26 aaa 0.50 ± 0.09bbb
Adrenals (μg/g) 626.0 ± 47.6 602.0 ± 66.7 433.1 ± 24.6a 579.4 ± 40.6
Brain (ng/g) 2.03 ± 0.09 2.38 ± 0.18 1.79 ± 0.25 2.57 ± 0.15 b
Serotonergic Measures
5-HT – Plasma (ng/ml) 18.56 ± 1.46 5.82 ± 0.60aaa 11.08 ± 0.65a 30.07±4.45bbb
Platelet (ng/ml) 556.7 ± 40.9 830.0±27.2aaa 1610.8±55.1aaa 1640.4±39.6
Brain (μg/g) 0.25 ± 0.01 0.30 ± 0.01a 0.24 ± 0.01 0.22 ± 0.01
5-HIAA – Plasma (ng/ml) 11.53 ± 0.93 17.56 ±1.20aa 18.00 ± 2.94a 25.07 ± 2.38b
Platelet (ng/ml) 3.92 ± 0.24 2.74 ± 0.18aa 2.99 ± 0.22a 3.68 ± 0.30
Brain (μg/g) 0.13 ± 0.004 0.12 ± 0.007 0.13 ± 0.005 0.13 ± 0.006
Results are means ± s.e.m. of n rats per group. aP<0.05, aaP<0.01 and aaaP<0.001 vs the sedentary group (control); bP<0.05, bbP<0.01 and bbbP<0.001 vs the 
Swimming group without rhEPO (exercise: EX). A, adrenaline; NA, noradrenaline; rhEPO, recombinant human erythropoietin; 5-HT, 5-hydroxy-tryptamine; 
5-HIAA, 5-hydroxyindoleacetic acid
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negative highlights of world sport, 
with recurrent news about the distor-
tion of sport values and ethics, by 
athletes, that, desperate to enhance 
their performance, try, illegally, to 
improve oxygen delivery to the mus-
cles by using rhEPO2,14,15. In endu-
rance sports, such as long-distance 
running, cycling and skiing, perfor-
mance relies on an adequate O2-sup-
ply to the heart and skeletal muscle. 
Hence, the rate of maximal O2-uptake 
is an important determinant of aero-
bic physical power. However, ath-
letes who abuse rhEPO seem to con-
sider only the benefi t to performance 
and ignore the short and long-term 
side-effects. There is a suspicion that 
rhEPO-induced erythrocytosis caused 
the death of about 20 world-class 
Dutch and Belgian Cyclists, although 
this was never proven8,9, probably 
due to the lack of methodological ca-
pacity to distinguish between the en-
dogenous and the recombinant EPO 
as well as due the lack of knowledge 
concerning the mechanisms underly-
ing the side-effects of rhEPO. When 
Lasne and de Ceaurriz4 were able to 
separate and distinguish by electro-
phoresis the endogenous and the 
rhEPO in human urine, the scandal 
of rhEPO use in sports was revealed, 
and the research and medical com-
munity was able to alert for the high 
health risks for the athletes.
The main risks of erythrocytosis 
(Hct>0.55 l/l) include heart failure, 
myocardial infarction, seizures, pe-
ripheral thromboembolic events and 
pulmonary embolism. Endurance 
athletes are at increased risk during 
the competition, if their blood viscos-
ity increases further due to the great 
loss of fl uid associated with swea-
ting6,8,9,15. The relationship between 
hematocrit and other hemorheologi-
cal parameters and performance was 
previously studied, particularly in or-
der to evaluate the paradox of hema-
tocrit in exercise physiology16-18, 
which is viewed as the discrepancy 
between the higher performance in 
artifi cially increased hematocrit, due 
Table V – Effects of rhEPO on serum infl ammatory profi le and redox status markers
Parameters
Sedentary Swimming
Control (n=7) rhEPO (n=7) EX (n=7) EX+rhEPO (n=7)
Infl ammatory Markers 
CRP (μg/mL) 26.68 ± 0.88 24.82 ± 0.76 24.22 ± 1.06 25.77 ± 1.21
IL-1β (pg/mL) 25.55 ± 1.69 25.95 ± 0.75 25.84 ± 1.38 23.96 ± 1.27
IL-2 (pg/mL) 44.67 ± 7.48 39.59 ± 4.75 51.48 ± 4.11 59.08 ± 3.76
TNF-α (pg/mL) 12.13 ± 0.65 14.18 ± 0.79a 12.62 ± 0.76 12.69 ± 0.59
TGF-β1 (pg/mL) 315.2 ± 13.2 380.2 ± 18.8a 317.8 ± 15.1 375.7 ± 23.5b
Redox Status
MDA (μmol/L) 0.40 ± 0.02  0.38 ± 0.04  0.30 ± 0.02a 0.34 ± 0.01
TAS (mmol/L) 0.24 ± 0.01 0.36 ± 0.03aaa 0.25 ± 0.01 0.22 ± 0.01
MDA/TAS (10-3) 1.76 ± 0.16 1.13 ± 0.23a  1.27 ± 0.09a 1.53 ± 0.05
3-NT (nmol/L) 42.42 ± 8.25 25.02 ± 3.58a 37.96 ± 7.31 42.26 ± 6.90
Results are means ± s.e.m. of n rats per group. aP<0.05, aaP<0.01 and aaaP<0.001 vs the sedentary group (control); bP<0.05, bbP<0.01 and bbbP<0.001 vs the 
Swimming group without rhEPO (exercise: EX). CRP, C-reactive protein; IL-1β, interleukin 1β; IL-2, interleukin 2; MDA, malondialdehyde; rhEPO, recom-
binant human erythropoietin; TAS, total antioxidant status; TGF-β1, transforming growth factor β1; TNF-α, tumour necrosis factor α; 3-NT, 3-nitrotyrosine
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to autotransfusion or rhEPO doping, 
versus the clear negative correlation 
between hematocrit and fi tness in 
normal conditions, due to training-
induced “autohemodilution”16. Ac-
cording to Brun et al., in highly 
trained professional footballers, the 
physiological values of hematocrit 
vary between 36 and 48%16. Further-
more, there was a higher aerobic ca-
pacity in "low" hematocrit (<40%) 
subjects, while in the higher hema-
tocrits (>44.6%) ones there was a 
trend to increased viscosity16.
The consequences of physical exer-
cise on the EPO concentrations have 
been poorly investigated. However, 
according to some data, exercise 
practise is able to reduce the serum 
EPO levels19. In a study with mara-
thon athletes under rhEPO treatment, 
serum EPO concentrations were in-
creased after both 3 and 31 hrs after 
exercise, but were unchanged imme-
diately after the end of running20. In 
our study, the rats under chronic ex-
ercise practice and rhEPO treatment 
showed several markers of increased 
cardiovascular/thromboembolic risk. 
The increased RBC count vs the EX 
group without rhEPO treatment was 
confi rmed, as expected. This was ac-
companied by development of hyper-
tension and tachycardia. Increased 
blood pressure is a common feature 
in patients and athletes under rhEPO 
treatment6,8,9,21, and might result both 
from increased blood viscosity and 
loss of hypoxia-induced vasodilata-
tion. rhEPO treatment was also able 
to promote heart hypertrophy, which 
might be due to the blood hypervis-
cosity and could be viewed as a need 
to ensure proper blood circulation to 
peripheral tissues. Increased tachy-
cardia might be explained by the in-
crement in sympathetic activity, re-
vealed by the higher values of plasma 
noradrenaline and adrenaline concen-
trations. This effect of rhEPO was 
previously documented, namely on 
hemodialyzed patients under rhEPO 
therapy22. Furthermore, there was an 
increment in plasma serotonergic 
measures, which might result from 
platelet overactivation, thus releasing 
the granule contents. The increased 
platelet reactivity was reported by 
others7, and is in favour of an in-
creased vascular reactivity, blood 
pressure and thromboembolic com-
plications.
rhEPO has been successfully 
used in anaemic patients to correct 
their anaemia. However, its effects 
on non-hematopoietic cells and tis-
sues, such as the brain and the heart, 
suggested new important insights to 
its use in other pathological condi-
tions, such as the ischemia-reper-
fusion, heart failure and neurode-
generative diseases23-28. The rationale 
for its potential use in those disor-
ders is based on its antioxidant, anti-
apoptotic and anti-inflammatory 
properties, already known as “pleio-
trophic actions”29-32. In our study, 
both the rhEPO treatment, per se, 
and the exercise practice have de-
monstrated a benefi cial effect on redox 
status markers. Therefore, rhEPO 
alone has promoted a signifi cant in-
crement in serum antioxidant capa-
city (TAS), together with a reduction 
of 3-nitrotyrosine content, a marker 
of peroxynitrite formation, which is 
in agreement with its action on other 
pathological circumstances29-32. 
Swimming rats also demonstrated 
antioxidant effects, given by the re-
duction of serum lipid peroxidation 
(MDA). However, rhEPO use in rats 
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under chronic aerobic exercise fa-
voured oxidative stress, viewed by 
the trend to higher values of serum 
redox status markers (MDA and 
3-NT) and lower of antioxidant ca-
pacity (TAS). These results, in view 
of the deleterious effect of ROS, 
might represent a clear increased 
cardiovascular risk.
The suggested serum pro-oxida-
tive pattern was accompanied by 
non-signifi cant changes of all serum 
infl ammatory markers, excepting the 
significant increment in TGF-β1, 
when compared with the exercised 
rats without rhEPO treatment. While 
the increase in the proliferation mar-
ker TGF-β1 might eventually explain 
the heart hypertrophy, the other non-
signifi cant results suggest that the 
deleterious effect of rhEPO in the rats 
under exercise is not mainly a conse-
quence of an exacerbated oxidative 
stress and infl ammation, but is prima-
rily a mechanic reaction as a result of 
increased blood viscosity. Therefore, 
the increased RBC will originate 
blood pressure and heart and left 
hypertrophy in order to improve the 
ability to transport the high-viscose 
blood, and the oxygen it carries, to 
peripheral tissue. The tachycardia 
further needed is most certainly orig-
inated by sympathetic overactivation. 
Thus, instead of specifi c effects of 
rhEPO on cellular/molecular mecha-
nisms related to infl ammation and 
oxidative stress pathways, the high 
cardiovascular and thromboembolic 
risk seems to be due to a physiologi-
cal response accompanied by growth 
factors increment and cardiac hyper-
trophy, which results in an undoubted 
life risk.
Our findings are in agreement 
with other studies, both in humans 
and animals under rhEPO treat-
ment. In end stage chronic kidney 
disease patients, for example, rhE-
PO is able to correct the associated 
anemia but there is hematocrit in-
crement, often associated with hy-
pertension, thromboembolism and 
higher morbidity and mortality33. In 
mice transgenic for EPO, the in-
creased hematocrit was linked with 
left and right ventricular hypertro-
phy and cardiac oedema, as well as 
with a reduced life expectancy34. 
Thus, erythrocytosis seems to in-
crease the risk for myocardial in-
farction and stroke, which was ob-
served in our experimental model 
of rhEPO sports doping in rats un-
der aerobic chronic exercise and 
rhEPO treatment.
In conclusion, in this animal 
model of doping, rhEPO use, in 
situations of chronic/regular physi-
cal exercise, promotes not only the 
expected increased hematocrit, but 
also other marked modifi cations in 
circulatory, infl ammatory and meta-
bolic parameters, that may be ex-
pected to be deleterious. Thus, the 
experimental results of Ht in the 
EX+rhEPO group may support ob-
servations in athletes submitted to 
erythropoietin doping, which might 
be submitted to a serious cardiovas-
cular and even live risk, which 
might be known and believed by all 
sports authorities and in particular 
by them and their physicians and 
themselves.
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